Skip to main content

Advertisement

Table 2 Rates of overall survival at 6 months and 1 year according to the RTOG RPA class, the HER-2 status and the delivery of trastuzumab

From: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

  n Median Survival
(months)
6 months
[CI95%]
1 year
[CI95%]
P value
Whole population 130 7.43 (5.52 -9.73) 54.9 [46.8; 64.3] 35.8 [28; 45.7]  
RTOG RPA     44.6 [34.3; 58.1] 0.001
Class I-II 78 9.63 (7.69-15.72) 65.9 [56; 77.5] 23.9 [14.2; 40.4]  
Class III 48 3.52 (2.86-7.36) 37.7 [26; 54.7]   
      0.004
HER-2 negative patients 78 5.88 [3.75; 9.63] 48.7 [37.7; 63] 26.1 [16.8; 40.7]  
HER-2 positive patients not treated with trastuzumab 20 5.65 [2.60; 12.49] 45.5 [31.3; 66.1] 29.2 [17-50.2]  
HER-2 positive patients treated with trastuzumab 32 19.53 [9.27; NA] 77.1 [63.5; 93.6] 62.6 [47.2; 83]  
Trastuzumab 10 9.17 (5.52-NA) 63.6 [40.7; 99.5] 43.6 [21.8; 87.4] 0.113
Stopped 22 20.91 (19.53-NA) 94.4 [84.4; 100] 88.5 [74.8; 100]  
Continued